Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 4Recruiting 3Terminated 2Unknown 1No longer available 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 5NET 4Gastrointestinal 3Sarcoma 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1

Conditions

Neuroendocrine Tumors 4

Interventions

Everolimus 19lutetium Lu 177 dotatate 8Octreotide 8lanreotide 7pasireotide 6Temozolomide 6Sunitinib 6pembrolizumab 5gallium Ga 68 dotatate 5Positron Emission Tomography Computed Tomography 5surufatinib 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Magnetic Resonance Spectroscopy 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × surufatinib × NET × Clear all
NCT05077384 2025-09-16

Open-label Study of Surufatinib in Japanese Patients

Hutchmed

Phase 1/2 Completed
36 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02588170 2023-03-30

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Hutchmed

Phase 3 Completed
219 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02589821 2023-03-30

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

Hutchmed

Phase 3 Completed
195 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02267967 2018-11-13

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

Hutchmed

Phase 1 Completed
81 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡